Clinical Scorecard: The Development of Clinical Trials for CNS Tumors by RTOG and NRG Oncology

At a Glance

Key Highlights

• RTOG/NRG trials have influenced evidence-based care for CNS tumors.

• Molecular stratification has demonstrated clinical significance in treatment outcomes.

• Temozolomide-based chemoradiation is the standard of care for glioblastoma.

• Advanced imaging and quality assurance have become integral to trial methodologies.

• Collaboration with other NCTN groups enhances trial development and patient enrollment.

Guideline-Based Recommendations

Diagnosis

• Incorporate molecular profiling for accurate tumor classification.

Management

• Utilize multimodal treatment strategies tailored to tumor biology.

Monitoring & Follow-up

• Integrate patient-reported outcomes and cognitive function assessments.

Risks

• Consider potential toxicity associated with intensified radiotherapy.

Patient & Prescribing Data

Patients with various types of CNS tumors, particularly gliomas.

Molecularly informed treatment approaches have shown varying benefits based on tumor genetics.

Clinical Best Practices

• Employ advanced imaging techniques for precise targeting in radiotherapy.

• Adopt standardized protocols for radiotherapy dose and fractionation.

• Ensure rigorous quality control in trial methodologies.

Related Resources & Content

1. jadpro — Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience

2. The ASCO Post — Failure of Cilengitide in Newly Diagnosed Glioblastoma With Methylated MGMT Promoter

3. The ASCO Post — Expert Point of View: Christina I. Tsien, MD Related Articles

4. Journal of Neuro-Oncology — Cognitive Effects of Treatment in Glioma Patients Over the Mid-Term

5. Management of Adverse Events in Early Clinical Trials

6. Failure of Cilengitide in Newly Diagnosed Glioblastoma

7. Expert Point of View: Christina I. Tsien, MD

8. Cognitive Effects of Treatment in Glioma Patients

9. ASCO-SNO Guideline Rapid Recommendation Update

10. ASTRO Clinical Practice Guideline

11. NCI's PDQ on CNS Tumors Treatment

12. Central Nervous System Tumors Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf

13. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001 - PMC

14. Long-term Analysis of NRG Oncology RTOG 0539: A Phase II Trial of Observation for Low-Risk Meningioma and Radiotherapy for Intermediate- and High-Risk Meningioma - PMC

15. Modern molecular profiling recontextualizes the NRG/RTOG 0539 trial and reveals hidden high-risk and radiotherapy-resistant meningiomas | Neuro-Oncology | Oxford Academic

16. NRG-BN003 - NRG Oncology

• RTOG 0825 Study